Table 1 Main characteristics of the selected studies
Citation | Mean age (years) | Number of patients | Duration of follow up (month) | Dose and frequency of crizotinib administration | Trial phase | Tumor histologic type (Adenocarcinoma, %) | Extent of disease (Metastatic, %) |
|---|---|---|---|---|---|---|---|
Shaw et al. [21] | 50.0 | 173 | 12.2 | 250 mg twice daily | Phase 3 | 95 | 95 |
Brosnan et al. [22] | 54.7 | 38 | 16.3 | 250 mg twice daily | NA | NA | NA |
Riely [23] | 53.0 | 261 | 12.0 | 250 mg twice daily | Phase 2 | 92 | NA |
Camidge et al. [19] | 52.0 | 149 | 16.3 | 250 mg twice daily | Phase 1 | 97 | NA |
Shaw et al. [20] | 51.0 | 56 | 18.0 | 250 mg twice daily | Phase 1 | 96 | 89 |
Kwak et al. [14] | 51.0 | 82 | 6.4 | 250 mg twice daily | Phase 1 | 96 | NA |